CoChat

Control of mRNA stability contributes to low levels of nuclear poly(A) binding protein 1 (PABPN1) in skeletal muscle

Apponi, Luciano H, Corbett, Anita H, Pavlath, Grace K · 2013 · Skeletal Muscle
Cited by 46

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background: The nuclear poly(A) binding protein 1 (PABPN1) is a ubiquitously expressed proteinthat plays critical roles at multiple steps in post-transcriptional regulation ofgene expression. Short expansions of the polyalanine tract in the N-terminus ofPABPN1 lead to oculopharyngeal muscular dystrophy (OPMD), which is an adult onsetdisease characterized by eyelid drooping, difficulty in swallowing, and weaknessin the proximal limb muscles. Why alanine-expanded PABPN1 leads to muscle-specificpathology is unknown. Given the general function of PABPN1 in RNA metabolism,intrinsic characteristics of skeletal muscle may make this tissue susceptible tothe effects of mutant PABPN1. Methods: To begin to understand the muscle specificity of OPMD, we investigated thesteady-state levels of PABPN1 in different tissues of humans and mice.Additionally, we analyzed the levels of PABPN1 during muscle regeneration afterinjury in mice. Furthermore, we assessed the dynamics of PABPN1 mRNA decay inskeletal muscle compared to kidney. Results: Here, we show that the steady-state levels of both PABPN1 mRNA and protein aredrastically lower in mouse and human skeletal muscle, particularly those impactedin OPMD, compared to other tissues. In contrast, PABPN1 levels are increasedduring muscle regeneration, suggesting a greater requirement for PABPN1 functionduring tissue repair. Further analysis indicates that modulation of PABPN1expression is likely due to post-transcriptional mechanisms acting at the level ofmRNA stability. Conclusions: Our results demonstrate that PABPN1 steady-state levels and likely control ofexpression differ significantly in skeletal muscle as compared to other tissues,which could have important implications for understanding the muscle-specificnature of OPMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2044-5040-3-23

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 39

  1. Kuhn U, Wahle E: Structure and function of poly(A) binding proteins. Biochim Biophys Acta. 2004, 1678: 67-84. 10.1016/j.bbaexp.2004.03.008. · DOI · Paper page
  2. Kerwitz Y, Kuhn U, Lilie H, Knoth A, Scheuermann T, Friedrich H, Schwarz E, Wahle E: Stimulation of poly(A) polymerase through a direct interaction with the nuclearpoly(A) binding protein allosterically regulated by RNA. EMBO J. 2003, 22: 3705-3714. 10.1093/emboj/cdg347. · DOI
  3. Kuhn U, Gundel M, Knoth A, Kerwitz Y, Rudel S, Wahle E: Poly(A) tail length is controlled by the nuclear poly(A)-binding proteinregulating the interaction between poly(A) polymerase and the cleavage andpolyadenylation specificity factor. J Biol Chem. 2009, 284: 22803-22814. 10.1074/jbc.M109.018226. · DOI · Paper page
  4. Jenal M, Elkon R, Loayza-Puch F, van Haaften G, Kühn U, Menzies FM, Oude Vrielink JA, Bos AJ, Drost J, Rooijers K, Rubinsztein DC, Agami R: The poly(A)-binding protein nuclear 1 suppresses alternative cleavage andpolyadenylation sites. Cell. 2012, 149: 538-553. 10.1016/j.cell.2012.03.022. · DOI · Paper page
  5. Lutz CS, Moreira A: Alternative mRNA polyadenylation in eukaryotes: an effective regulator of geneexpression. Wiley Interdiscip Rev RNA. 2011, 2: 22-31. 10.1002/wrna.47. · DOI · Paper page
  6. Beaulieu YB, Kleinman CL, Landry-Voyer AM, Majewski J, Bachand F: Polyadenylation-dependent control of long noncoding RNA expression by thepoly(A)-binding protein nuclear 1. PLoS Genet. 2012, 8: e1003078-10.1371/journal.pgen.1003078. · DOI · Paper page
  7. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chrétien N, Tomé FM, Lafrenière RG, Rommens JM, Uyama E, Nohira O, Blumen S, Korczyn AD, Heutink P, Mathieu J, Duranceau A, Codère F, Fardeau M, Rouleau GA: Short GCG expansions in the PABP2 gene cause oculopharyngeal musculardystrophy. Nat Genet. 1998, 18: 164-167. 10.1038/ng0298-164. · DOI · Paper page
  8. Victor M, Hayes R, Adams RD: Oculopharyngeal muscular dystrophy. A familial disease of late life characterizedby dysphagia and progressive ptosis of the evelids. N Engl J Med. 1962, 267: 1267-1272. 10.1056/NEJM196212202672501. · doi:10.1056/nejm196212202672501
  9. Ruegg S, Lehky Hagen M, Hohl U, Kappos L, Fuhr P, Plasilov M, Muller H, Heinimann K: Oculopharyngeal muscular dystrophy - an under-diagnosed disorder?. Swiss Med Wkly. 2005, 135: 574-586.
  10. Van Der Sluijs BM, Hoefsloot LH, Padberg GW, Van Der Maarel SM, Van Engelen BG: Oculopharyngeal muscular dystrophy with limb girdle weakness as majorcomplaint. J Neurol. 2003, 250: 1307-1312. 10.1007/s00415-003-0201-6. · doi:10.1007/s00415-003-0201-6
  11. Abu-Baker A, Rouleau GA: Oculopharyngeal muscular dystrophy: recent advances in the understanding of themolecular pathogenic mechanisms and treatment strategies. Biochim Biophys Acta. 2007, 1772: 173-185. 10.1016/j.bbadis.2006.10.003. · DOI
  12. Tome FM, Fardeau M: Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol. 1980, 49: 85-87. 10.1007/BF00692226. · DOI
  13. Tome FM, Chateau D, Helbling-Leclerc A, Fardeau M: Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. Neuromuscul Disord. 1997, 7 (Suppl 1): S63-S69. · DOI
  14. Banerjee A, Apponi LH, Pavlath GK, Corbett AH: PABPN1: Molecular function and muscle disease. FEBS J. 2013, 280: 4230-4250. 10.1111/febs.12294. · DOI · Paper page
  15. Apponi LH, Leung SW, Williams KR, Valentini SR, Corbett AH, Pavlath GK: Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNAbiogenesis. Hum Mol Genet. 2010, 19: 1058-1065. 10.1093/hmg/ddp569. · DOI · Paper page
  16. O’Connor RS, Mills ST, Jones KA, Ho SN, Pavlath GK: A combinatorial role for NFAT5 in both myoblast migration and differentiationduring skeletal muscle myogenesis. J Cell Sci. 2007, 120: 149-159. · DOI
  17. Bondesen BA, Mills ST, Kegley KM, Pavlath GK: The COX-2 pathway is essential during early stages of skeletal muscleregeneration. Am J Physiol Cell Physiol. 2004, 287: C475-C483. 10.1152/ajpcell.00088.2004. · DOI · Paper page
  18. Ausubel FM, Brent R, Kingston ER, Moore DD, Seidman JG, Smith JA, Struhl K: Current Protocols in Molecular Biology. 2001, New York, NY: John Wiley and Sons · DOI · Paper page
  19. Workman JL, Kingston RE: Alteration of nucleosome structure as a mechanism of transcriptionalregulation. Ann Rev Biochem. 1998, 67: 545-579. 10.1146/annurev.biochem.67.1.545. · DOI · Paper page
  20. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G: The 90-kDa molecular chaperone family: structure, function, and clinicalapplications. A comprehensive review. Pharmacol Ther. 1998, 79: 129-168. 10.1016/S0163-7258(98)00013-8. · DOI · Paper page
  21. Nemeth A, Krause S, Blank D, Jenny A, Jeno P, Lustig A, Wahle E: Isolation of genomic and cDNA clones encoding bovine poly(A) binding proteinII. Nucleic Acids Res. 1995, 23: 4034-4041. 10.1093/nar/23.20.4034. · DOI
  22. Lee YJ, Lee J, Yang IC, Hahn Y, Lee Y, Chung JH: Genomic structure and expression of murine poly(A) binding protein II gene. Biochim Biophys Acta. 1998, 1395: 40-46. 10.1016/S0167-4781(97)00147-4. · doi:10.1016/s0167-4781(97)00147-4
  23. Bentzinger CF, Wang YX, Rudnicki MA: Building muscle: molecular regulation of myogenesis. old Spring Harb Perspec Biol. 2012, 4: pii:a008342-
  24. Lai RY, Ljubicic V, D’Souza D, Hood DA: Effect of chronic contractile activity on mRNA stability in skeletal muscle. Am J Physiol Cell Physiol. 2010, 299: C155-C163. 10.1152/ajpcell.00523.2009. · DOI · Paper page
  25. Zhang L, Lee JE, Wilusz J, Wilusz CJ: The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNAin muscle cells: implications for myotonic dystrophy. J Biol Chem. 2008, 283: 22457-22463. 10.1074/jbc.M802803200. · DOI · Paper page
  26. Lee JE, Lee JY, Wilusz J, Tian B, Wilusz CJ: Systematic analysis of cis-elements in unstable mRNAs demonstrates that CUGBP1 isa key regulator of mRNA decay in muscle cells. PloS One. 2010, 5: e11201-10.1371/journal.pone.0011201. · DOI · Paper page
  27. Thorrez L, Van Deun K, Tranchevent LC, Van Lommel L, Engelen K, Marchal K, Moreau Y, Van Mechelen I, Schuit F: Using ribosomal protein genes as reference: a tale of caution. PloS One. 2008, 3: e1854-10.1371/journal.pone.0001854. · DOI · Paper page
  28. Hsiao LL, Dangond F, Yoshida T, Hong R, Jensen RV, Misra J, Dillon W, Lee KF, Clark KE, Haverty P, Weng Z, Mutter GL, Frosch MP, MacDonald ME, Milford EL, Crum CP, Bueno R, Pratt RE, Mahadevappa M, Warrington JA, Stephanopoulos G, Stephanopoulos G, Gullans SR: A compendium of gene expression in normal human tissues. Physiol Genomics. 2001, 7: 97-104. · DOI · Paper page
  29. Welle S, Bhatt K, Thornton CA: Inventory of high-abundance mRNAs in skeletal muscle of normal men. Genome Res. 1999, 9: 506-513. · DOI · Paper page
  30. Gingerich TJ, Feige JJ, LaMarre J: AU-rich elements and the control of gene expression through regulated mRNAstability. Anim Health Res Rev. 2004, 5: 49-63. 10.1079/AHR200460. · DOI
  31. Wilusz CJ, Wilusz J: Bringing the role of mRNA decay in the control of gene expression into focus. Trends Genet. 2004, 20: 491-497. 10.1016/j.tig.2004.07.011. · DOI · Paper page
  32. Barreau C, Paillard L, Osborne HB: AU-rich elements and associated factors: are there unifying principles?. Nucleic Acids Res. 2005, 33: 7138-7150. 10.1093/nar/gki1012. · DOI · Paper page
  33. Zoghbi HY, Orr HT: Polyglutamine diseases: protein cleavage and aggregation. Curr Opin Neurobiol. 1999, 9: 566-570. 10.1016/S0959-4388(99)00013-6. · DOI
  34. Nasrallah IM, Minarcik JC, Golden JA: A polyalanine tract expansion in Arx forms intranuclear inclusions and results inincreased cell death. J Cell Biol. 2004, 167: 411-416. 10.1083/jcb.200408091. · DOI
  35. Caburet S, Demarez A, Moumne L, Fellous M, De Baere E, Veitia RA: A recurrent polyalanine expansion in the transcription factor FOXL2 inducesextensive nuclear and cytoplasmic protein aggregation. J Med Genet. 2004, 41: 932-936. 10.1136/jmg.2004.024356. · doi:10.1136/jmg.2004.024356
  36. Winter R, Liebold J, Schwarz E: The unresolved puzzle why alanine extensions cause disease. Biol Chem. 2013, 394: 951-963. · DOI
  37. Berciano MT, Villagra NT, Ojeda JL, Navascues J, Gomes A, Lafarga M, Carmo-Fonseca M: Oculopharyngeal muscular dystrophy-like nuclear inclusions are present in normalmagnocellular neurosecretory neurons of the hypothalamus. Hum Mol Genet. 2004, 13: 829-838. 10.1093/hmg/ddh101. · DOI
  38. Anvar SY, Raz Y, Verway N, van der Sluijs B, Venema A, Goeman JJ, Vissing J, van der Maarel SM, t Hoen PA, van Engelen BG, Raz V: A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscledystrophy and in muscle aging. Aging. 2013, 5: 412-426. · DOI
  39. Davies JE, Sarkar S, Rubinsztein DC: Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngealmuscular dystrophy mutation. Hum Mol Genet. 2008, 17: 1097-1108. 10.1093/hmg/ddm382. · DOI

Metadata

Authors
Apponi, L. H., Corbett, A. H., & Pavlath, G. K.
Venue
Skeletal Muscle
Published
2013-10-01
Volume
3
Issue
1
ISSN
2044-5040
Cited by
46
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Control of mRNA stability contributes to low levels of nuclear poly(A) binding protein 1 (PABPN1) in skeletal muscle. https://app.cochat.ai/papers/10.1186/2044-5040-3-23
The paper
Apponi, L. H., Corbett, A. H., & Pavlath, G. K. (2013). Control of mRNA stability contributes to low levels of nuclear poly(A) binding protein 1 (PABPN1) in skeletal muscle. Skeletal Muscle. https://doi.org/10.1186/2044-5040-3-23

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.